Additionally, Unity Biotechnology also announced 3 Yehia Hashad, MD, executive vice president of research and development and ...

The market was seeing Ocular Therapeutix (NASDAQ: OCUL) very positively this week, and that sunny view pushed the company's stock higher. As of Friday morning before market open, the eye care ...

Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris. WINNIPEG, ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly ...

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.